Literature DB >> 10775789

Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice.

E P Kelly1, J J Greene, A D King, B L Innis.   

Abstract

The full-length dengue 2 virus envelope glycoprotein (Egp) was expressed in insect cells by recombinant (r) baculovirus and found to form multimeric aggregates that were recovered in the void volume of gel filtration columns and by ultracentrifugation. An immunoblot confirmed that rEgp aggregrates disrupted with SDS sample buffer released a monomeric form that migrated with a molecular weight similar to native dengue 2 virus Egp on polyacrylamide gels. The rEgp aggregates reacted strongly with a panel of monoclonal antibodies specific for the native Egp and which identify critical structural and functional epitopes. The rEgp aggregates were purified by ultracentrifugation through 30% sucrose, and were shown to be the major protein band on a polyacrylamide gel and corresponding immunoblot. Purified rEgp aggregates in combination with aluminum hydroxide induced high titer neutralizing antibodies in adult mice. The generation of full-length dengue 2 rEgp aggregates in insect cells facilitated development of a simple, effective procedure for purification of the recombinant protein, and represents a good approach for producing highly immunogenic dengue 2 rEgp as a component of a subunit vaccine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10775789     DOI: 10.1016/s0264-410x(00)00032-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2.

Authors:  Smita Jaiswal; Navin Khanna; S Swaminathan
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

2.  Dengue virus E glycoprotein production in transgenic rice callus.

Authors:  Tae-Geum Kim; Mi-Young Kim; Nguyen-Quang-Duc Tien; Nguyen-Xuan Huy; Moon-Sik Yang
Journal:  Mol Biotechnol       Date:  2014-12       Impact factor: 2.695

3.  Purification, stability, and immunogenicity analyses of five bluetongue virus proteins for use in development of a subunit vaccine that allows differentiation of infected from vaccinated animals.

Authors:  Jenna Anderson; Emmanuel Bréard; Karin Lövgren Bengtsson; Kjell-Olov Grönvik; Stéphan Zientara; Jean-Francois Valarcher; Sara Hägglund
Journal:  Clin Vaccine Immunol       Date:  2014-01-22

4.  An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.

Authors:  Akane Urakami; Mya Myat Ngwe Tun; Meng Ling Moi; Atsuko Sakurai; Momoko Ishikawa; Sachiko Kuno; Ryuji Ueno; Kouichi Morita; Wataru Akahata
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

5.  Chimeric derivatives of hepatitis B virus core particles carrying major epitopes of the rubella virus E1 glycoprotein.

Authors:  Dace Skrastina; Ivars Petrovskis; Rasa Petraityte; Irina Sominskaya; Velta Ose; Ilva Lieknina; Janis Bogans; Kestutis Sasnauskas; Paul Pumpens
Journal:  Clin Vaccine Immunol       Date:  2013-09-04

Review 6.  The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.

Authors:  Beth-Ann G Coller; David E Clements; Andrew J Bett; Sangeetha L Sagar; Jan H Ter Meulen
Journal:  Vaccine       Date:  2011-07-21       Impact factor: 3.641

7.  Expression of dengue-3 premembrane and envelope polyprotein in lettuce chloroplasts.

Authors:  Anderson Paul Kanagaraj; Dheeraj Verma; Henry Daniell
Journal:  Plant Mol Biol       Date:  2011-03-24       Impact factor: 4.076

8.  Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model.

Authors:  Thomas J Chambers; Yan Liang; Deborah A Droll; Jacob J Schlesinger; Andrew D Davidson; Peter J Wright; Xiaoshan Jiang
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

9.  Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens.

Authors:  Miwa Kuwahara; Eiji Konishi
Journal:  Clin Vaccine Immunol       Date:  2010-07-28

10.  Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.

Authors:  Ashlie Thomas; Devina J Thiono; Stephan T Kudlacek; John Forsberg; Lakshmanane Premkumar; Shaomin Tian; Brian Kuhlman; Aravinda M de Silva; Stefan W Metz
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.